Physician profile
Bonnie E Appler
NPI 1871721266
$49,785.64
in general payments reported to CMS, 2019-2025
37 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $2,389 · 2023: $1,508 · 2024: $4,588 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $11K · Consulting Fee: $6,928 · Travel and Lodging: $4,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,293.00 |
| Food and Beverage | $11,347.13 |
| Consulting Fee | $6,927.50 |
| Travel and Lodging | $4,576.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15,638.86 | 2021-2025 | |
| Esperion Therapeutics, INC. | $12,596.54 | 2021-2025 | Nexletol |
| Ionis Pharmaceuticals, INC. | $6,484.77 | 2025 | Olezarsen, Tryngolza |
| Regeneron Healthcare Solutions, INC. | $4,055.34 | 2021-2025 | Evkeeza |
| Amgen INC. | $2,535.60 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $1,181.50 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,011.67 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $994.35 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $984.86 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Alnylam Pharmaceuticals INC. | $422.13 | 2024-2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $412.69 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $400.16 | 2024-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $398.12 | 2023-2025 | Verquvo |
| Abiomed | $339.50 | 2023-2024 | Impella |
| Novo Nordisk INC | $303.77 | 2021-2025 | Wegovy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $286.06 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $270.43 | 2021-2024 | Xarelto |
| Abbott Laboratories | $212.36 | 2021-2025 | Cardiomems |
| Boston Scientific Corporation | $179.46 | 2021-2025 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $154.07 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $151.61 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $136.24 | 2024-2025 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $112.50 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $85.92 | 2021-2024 | |
| Philips North America LLC | $72.79 | 2024-2025 | Extended Holter, (Ck4) Mcot |
| Medtronic, INC. | $59.12 | 2024-2025 | Symplicity G3, Cg Future |
| Atricure, INC. | $40.96 | 2024 | |
| Daiichi Sankyo INC. | $37.30 | 2023 | Injectafer |
| Altathera Pharmaceuticals LLC | $34.09 | 2024 | Sotalol Hydrochloride |
| Bridgebio Pharma, INC. | $30.13 | 2025 | Attruby |
| Genzyme Corporation | $27.65 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $26.96 | 2024 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $25.61 | 2021-2022 | |
| Biotronik INC. | $23.45 | 2022 | |
| United Therapeutics Corporation | $20.90 | 2021 | |
| Amryt Pharma Holdings LTD | $19.87 | 2021 | |
| Lilly USA, LLC | $18.30 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Appler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.